UroGen (URGN) 2025 Earnings: What Investors Should Know
As UroGen prepares to report 2025 results, investors weigh Jelmyto sales, pipeline progress, and balance-sheet health...
This comparison highlights essential contrasts between Zero Based and Incremental budgeting, focusing on allocation, rigor, and outcomes.
17,126 articlesAs UroGen prepares to report 2025 results, investors weigh Jelmyto sales, pipeline progress, and balance-sheet health...
When blue-chip allocators signal interest in a landmark IPO, it reshapes how individual investors view the stock. Thi...
Energy markets moved on geopolitical headlines, lifting ConocoPhillips stock in intraday trading. This article explai...
ON Semiconductor rides AI data-center demand and EV silicon trends to extend its rally, but analysts warn that valuat...
Thor Industries reports a dramatic EPS surprise for Q2, with revenue rising modestly. Yet cash flow weakness and unev...
When a top executive sells a large block of stock, investors want to know whether it signals trouble or simply person...
Regulatory rhetoric around the Clarity Act ignites a fresh XRP debate, with Cardano founder Charles Hoskinson warning...
A regional wealth manager quietly deploys AI to streamline onboarding and risk controls, delivering a secrets unheral...
Dogecoin shot to fame and then faded, but savvy investors still wonder about its future. This guide breaks down the o...
A Cytokinetics insider sale coincides with a stunning stock move. This article breaks down what the trade might signa...
A major institutional move is shaping Balchem's next chapter. As the company posts record sales, a new investor stake...
With American Express set to report on July 24, analysts say a durable franchise, disciplined capital returns, and a ...